S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:SNGX

Soligenix Competitors

$1.65
-0.03 (-1.79 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.57
Now: $1.65
$1.71
50-Day Range
$1.38
MA: $1.69
$2.35
52-Week Range
$1.21
Now: $1.65
$3.20
Volume1.29 million shs
Average Volume5.27 million shs
Market Capitalization$51.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42

Competitors

Soligenix (NASDAQ:SNGX) Vs. CALA, CNCE, OPTN, MDNA, SCPH, and NOVN

Should you be buying SNGX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Soligenix, including Calithera Biosciences (CALA), Concert Pharmaceuticals (CNCE), OptiNose (OPTN), Medicenna Therapeutics (MDNA), scPharmaceuticals (SCPH), and Novan (NOVN).

Calithera Biosciences (NASDAQ:CALA) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Earnings and Valuation

This table compares Calithera Biosciences and Soligenix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera Biosciences$22.25 million9.26$-89,860,000.00($1.90)-1.54
Soligenix$4.60 million11.29$-9,360,000.00($0.48)-3.44

Soligenix has lower revenue, but higher earnings than Calithera Biosciences. Soligenix is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Calithera Biosciences and Soligenix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Calithera Biosciences01402.80
Soligenix02202.50

Calithera Biosciences presently has a consensus price target of $5.3333, suggesting a potential upside of 82.65%. Soligenix has a consensus price target of $3.4375, suggesting a potential upside of 108.33%. Given Soligenix's higher possible upside, analysts plainly believe Soligenix is more favorable than Calithera Biosciences.

Volatility and Risk

Calithera Biosciences has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Calithera Biosciences and Soligenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Calithera BiosciencesN/A-66.64%-56.60%
Soligenix-567.04%-328.25%-140.08%

Institutional & Insider Ownership

74.0% of Calithera Biosciences shares are owned by institutional investors. Comparatively, 9.4% of Soligenix shares are owned by institutional investors. 11.9% of Calithera Biosciences shares are owned by company insiders. Comparatively, 3.1% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Calithera Biosciences beats Soligenix on 10 of the 14 factors compared between the two stocks.

Concert Pharmaceuticals (NASDAQ:CNCE) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Concert Pharmaceuticals and Soligenix's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concert Pharmaceuticals$1.08 million189.85$-78,170,000.00($3.29)-2.03
Soligenix$4.60 million11.29$-9,360,000.00($0.48)-3.44

Soligenix has higher revenue and earnings than Concert Pharmaceuticals. Soligenix is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Concert Pharmaceuticals and Soligenix, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concert Pharmaceuticals00503.00
Soligenix02202.50

Concert Pharmaceuticals presently has a consensus price target of $21.00, suggesting a potential upside of 213.90%. Soligenix has a consensus price target of $3.4375, suggesting a potential upside of 108.33%. Given Concert Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Concert Pharmaceuticals is more favorable than Soligenix.

Risk & Volatility

Concert Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Profitability

This table compares Concert Pharmaceuticals and Soligenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concert Pharmaceuticals-921.38%-55.20%-44.83%
Soligenix-567.04%-328.25%-140.08%

Institutional and Insider Ownership

69.7% of Concert Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of Soligenix shares are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Concert Pharmaceuticals beats Soligenix on 9 of the 14 factors compared between the two stocks.

Soligenix (NASDAQ:SNGX) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Soligenix and OptiNose, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Soligenix02202.50
OptiNose01202.67

Soligenix currently has a consensus target price of $3.4375, indicating a potential upside of 108.33%. OptiNose has a consensus target price of $19.00, indicating a potential upside of 389.69%. Given OptiNose's stronger consensus rating and higher probable upside, analysts clearly believe OptiNose is more favorable than Soligenix.

Profitability

This table compares Soligenix and OptiNose's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Soligenix-567.04%-328.25%-140.08%
OptiNose-230.14%-294.64%-59.29%

Institutional & Insider Ownership

9.4% of Soligenix shares are owned by institutional investors. Comparatively, 62.9% of OptiNose shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 38.0% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Soligenix has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, OptiNose has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Valuation & Earnings

This table compares Soligenix and OptiNose's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soligenix$4.60 million11.29$-9,360,000.00($0.48)-3.44
OptiNose$34.63 million5.84$-110,050,000.00($2.63)-1.48

Soligenix has higher earnings, but lower revenue than OptiNose. Soligenix is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

OptiNose beats Soligenix on 9 of the 13 factors compared between the two stocks.

Soligenix (NASDAQ:SNGX) and Medicenna Therapeutics (NASDAQ:MDNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Earnings & Valuation

This table compares Soligenix and Medicenna Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soligenix$4.60 million11.29$-9,360,000.00($0.48)-3.44
Medicenna TherapeuticsN/AN/A$-6,220,000.00($0.19)-20.58

Medicenna Therapeutics has lower revenue, but higher earnings than Soligenix. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.4% of Soligenix shares are held by institutional investors. Comparatively, 3.9% of Medicenna Therapeutics shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Soligenix and Medicenna Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Soligenix02202.50
Medicenna Therapeutics00403.00

Soligenix currently has a consensus target price of $3.4375, indicating a potential upside of 108.33%. Medicenna Therapeutics has a consensus target price of $10.00, indicating a potential upside of 155.75%. Given Medicenna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Medicenna Therapeutics is more favorable than Soligenix.

Volatility and Risk

Soligenix has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Profitability

This table compares Soligenix and Medicenna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Soligenix-567.04%-328.25%-140.08%
Medicenna TherapeuticsN/A-40.19%-37.66%

Summary

Medicenna Therapeutics beats Soligenix on 8 of the 13 factors compared between the two stocks.

scPharmaceuticals (NASDAQ:SCPH) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares scPharmaceuticals and Soligenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
scPharmaceuticalsN/A-44.04%-32.52%
Soligenix-567.04%-328.25%-140.08%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for scPharmaceuticals and Soligenix, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
scPharmaceuticals01202.67
Soligenix02202.50

scPharmaceuticals presently has a consensus price target of $12.3333, indicating a potential upside of 67.12%. Soligenix has a consensus price target of $3.4375, indicating a potential upside of 108.33%. Given Soligenix's higher probable upside, analysts plainly believe Soligenix is more favorable than scPharmaceuticals.

Valuation & Earnings

This table compares scPharmaceuticals and Soligenix's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
scPharmaceuticalsN/AN/A$-33,000,000.00($1.77)-4.17
Soligenix$4.60 million11.29$-9,360,000.00($0.48)-3.44

Soligenix has higher revenue and earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

scPharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

62.5% of scPharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of Soligenix shares are held by institutional investors. 4.1% of scPharmaceuticals shares are held by insiders. Comparatively, 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Soligenix (NASDAQ:SNGX) and Novan (NASDAQ:NOVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Soligenix and Novan, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Soligenix02202.50
Novan00103.00

Soligenix presently has a consensus price target of $3.4375, indicating a potential upside of 108.33%. Novan has a consensus price target of $1.50, indicating a potential upside of 5.63%. Given Soligenix's higher probable upside, analysts clearly believe Soligenix is more favorable than Novan.

Institutional and Insider Ownership

9.4% of Soligenix shares are held by institutional investors. Comparatively, 6.2% of Novan shares are held by institutional investors. 3.1% of Soligenix shares are held by company insiders. Comparatively, 3.0% of Novan shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Soligenix and Novan's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Soligenix-567.04%-328.25%-140.08%
Novan-379.35%N/A-43.81%

Earnings & Valuation

This table compares Soligenix and Novan's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soligenix$4.60 million11.29$-9,360,000.00($0.48)-3.44
Novan$4.90 million43.70$-30,640,000.00($0.80)-1.78

Soligenix has higher earnings, but lower revenue than Novan. Soligenix is trading at a lower price-to-earnings ratio than Novan, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Soligenix has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Novan has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.

Summary

Soligenix beats Novan on 8 of the 14 factors compared between the two stocks.

Ad Traders News Media
Miss this “Ultima Event” at your own financial risk
Some of the smartest people I know have been texting me, relieved to have successfully claimed their seat - so I wanted you to know about it before it’s too late.

Soligenix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Calithera Biosciences logo
CALA
Calithera Biosciences
1.7$2.92-0.3%$206.03 million$22.25 million-2.12
Concert Pharmaceuticals logo
CNCE
Concert Pharmaceuticals
1.7$6.69-2.7%$205.04 million$1.08 million-2.60Earnings Announcement
Decrease in Short Interest
OptiNose logo
OPTN
OptiNose
1.6$3.88-3.6%$202.07 million$34.63 million-1.76Upcoming Earnings
Increase in Short Interest
MDNA
Medicenna Therapeutics
0.7$3.91-3.1%$201.65 millionN/A-19.55Increase in Short Interest
scPharmaceuticals logo
SCPH
scPharmaceuticals
1.3$7.38-1.5%$201.63 millionN/A-4.56
Novan logo
NOVN
Novan
0.9$1.42-12.7%$200.95 million$4.90 million-6.45Gap Up
Iterum Therapeutics logo
ITRM
Iterum Therapeutics
1.2$1.64-6.7%$198.69 million$40,000.00-0.40Increase in Short Interest
Gap Up
TLC
Taiwan Liposome
1.2$5.34-1.3%$198.10 million$6.99 million-6.67Upcoming Earnings
Decrease in Short Interest
Harrow Health logo
HROW
Harrow Health
1.7$7.67-0.1%$197.47 million$51.17 million-95.88Upcoming Earnings
News Coverage
vTv Therapeutics logo
VTVT
vTv Therapeutics
1.6$2.66-4.5%$196.52 million$2.76 million-6.05Earnings Announcement
High Trading Volume
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.4$3.04-4.6%$195.19 million$3.05 million-4.28Upcoming Earnings
Decrease in Short Interest
Atossa Therapeutics logo
ATOS
Atossa Therapeutics
1.2$2.72-7.0%$194.68 millionN/A-2.01Decrease in Short Interest
Tiziana Life Sciences logo
TLSA
Tiziana Life Sciences
1.2$3.01-1.0%$193.30 millionN/A-100.33
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.3$7.91-4.2%$191.53 million$460,000.00-6.65Upcoming Earnings
FSDC
FS Development
0.3$12.66-2.2%$190.24 millionN/A0.00
Exicure logo
XCUR
Exicure
1.5$2.17-3.7%$190.09 million$1.30 million-8.35
ObsEva logo
OBSV
ObsEva
1.4$3.90-0.3%$187.20 millionN/A-1.57Upcoming Earnings
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.7$2.95-0.0%$187.13 millionN/A-2.09
Lantern Pharma logo
LTRN
Lantern Pharma
1.2$17.77-5.1%$186.64 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Gap Down
PANA
Panacea Acquisition
0.0$10.42-1.2%$185.11 millionN/A0.00
Corbus Pharmaceuticals logo
CRBP
Corbus Pharmaceuticals
1.7$2.18-6.0%$183.20 million$36.14 million-1.22Increase in Short Interest
Heat Biologics logo
HTBX
Heat Biologics
1.6$7.98-0.9%$182.22 million$3.05 million0.00
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$8.90-4.6%$181.47 million$22.90 million-6.69
Kindred Biosciences logo
KIN
Kindred Biosciences
1.5$4.51-1.8%$178.11 million$4.26 million-6.54
Equillium logo
EQ
Equillium
1.9$7.05-7.7%$174.52 millionN/A-4.49Increase in Short Interest
Gap Up
DiaMedica Therapeutics logo
DMAC
DiaMedica Therapeutics
1.5$9.17-0.9%$171.84 million$500,000.00-12.07
AcelRx Pharmaceuticals logo
ACRX
AcelRx Pharmaceuticals
1.3$1.88-3.2%$170.10 million$2.29 million-3.36Decrease in Short Interest
Gap Up
ENOB
Enochian Biosciences
0.5$3.54-7.1%$169.08 millionN/A0.00
ASLAN Pharmaceuticals logo
ASLN
ASLAN Pharmaceuticals
1.0$4.43-0.7%$168.30 million$3 million-4.10Increase in Short Interest
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$5.08-8.9%$167.75 million$15.96 million-3.08Analyst Report
Analyst Revision
Gap Up
Sierra Oncology logo
SRRA
Sierra Oncology
1.8$14.74-1.8%$162.74 millionN/A-1.05Upcoming Earnings
Increase in Short Interest
ORGS
Orgenesis
0.3$6.69-3.0%$161.60 million$33.26 million1.44
Clearside Biomedical logo
CLSD
Clearside Biomedical
1.6$3.31-1.8%$160.05 million$2.17 million-10.34Increase in Short Interest
GlycoMimetics logo
GLYC
GlycoMimetics
1.7$3.32-3.0%$158.79 millionN/A-2.94Upcoming Earnings
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$2.97-2.7%$158.67 million$380,000.000.00Gap Down
Biofrontera logo
BFRA
Biofrontera
1.2$6.54-3.8%$156.14 million$35.02 million-8.49Increase in Short Interest
Aquestive Therapeutics logo
AQST
Aquestive Therapeutics
1.7$4.58-10.0%$153.98 million$52.61 million-2.99
OncoSec Medical logo
ONCS
OncoSec Medical
1.6$5.50-0.0%$153.95 millionN/A-2.24
Oncolytics Biotech logo
ONCY
Oncolytics Biotech
1.2$3.21-8.1%$153.08 millionN/A-3.96Upcoming Earnings
Decrease in Short Interest
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.3$2.03-1.5%$152.16 millionN/A0.00
Adamis Pharmaceuticals logo
ADMP
Adamis Pharmaceuticals
1.1$1.12-0.9%$150.30 million$22.11 million-2.33Decrease in Short Interest
Eyenovia logo
EYEN
Eyenovia
1.3$5.93-1.7%$147.56 millionN/A-5.39Decrease in Short Interest
ContraFect logo
CFRX
ContraFect
1.4$5.25-1.5%$146.00 millionN/A-1.97
Adamas Pharmaceuticals logo
ADMS
Adamas Pharmaceuticals
1.5$4.75-0.0%$145.20 million$54.64 million-2.15Earnings Announcement
Decrease in Short Interest
Analyst Revision
Aptevo Therapeutics logo
APVO
Aptevo Therapeutics
0.9$32.71-3.3%$143.24 million$32.42 million-2.14
Liminal BioSciences logo
LMNL
Liminal BioSciences
1.1$4.80-3.1%$141.05 million$3.70 million-1.63Increase in Short Interest
Gap Up
Otonomy logo
OTIC
Otonomy
1.7$2.91-1.4%$140.85 million$600,000.00-2.19Gap Up
Leap Therapeutics logo
LPTX
Leap Therapeutics
1.5$2.33-5.6%$139.00 millionN/A-2.14Gap Up
Aytu BioScience logo
AYTU
Aytu BioScience
1.7$7.67-3.0%$137.16 million$27.63 million0.00
Catalyst Biosciences logo
CBIO
Catalyst Biosciences
1.4$6.03-1.5%$133.25 million$10,000.00-1.88Upcoming Earnings
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.